Chong Kun Dang is starting to develop new anti-cancer drugs with Antibody drug conjugate (ADC) technology.
Chong Kun Dang announced today that it has signed a contract to introduce antibody-drug conjugate technology with Synaffix B.V, a Dutch biotechnology company, on February 3.
The size of the contract is approximately $132 million (approximately KRW 165 billion), including down payment, development, permitting, and sales milestones. After commercialization, royalties for each stage of sales are set separately.
With this contract, Chong Kun Dang plans to secure the right to use Synaffix B.V's three antibody-drug conjugate platform technologies, GlycoConnect™, HydraSpace™, and toxSYN™, to develop ADC anti-cancer drugs.
Synaffix B.V's ADC platform technology is a next-generation technology that can realize site-specific conjugation by conjugating an exact number of drugs to an antibody at a precise location.
While other technologies require antibody modification, Synaffix B.V's technology has superior efficacy than existing ADCs as it can apply previously discovered antibodies as ADCs without modification. In addition, this technology enables safe and efficient production from toxicity.
Since 2019, Chong Kun Dang has conducted joint research with Synaffix B.V to discover competitive ADCs and secured ADCs with superior efficacy and safety compared to existing ADCs.
“Through this contract with Synaffix B.V., we will speed up the development of next-generation anticancer drugs that will lead the global market,” said Chong Kun Dang CEO Kim Young-joo.
